#peg2

[moleculardepot]

BSA-PEG2-Xylazine Conjugate

BSA-PEG2-Xylazine Conjugate Catalog number: B2022012 Lot number: Batch Dependent Expiration Date: Batch dependent Amount: 500 µg Molecular Weight or Concentration: N/A Supplied as: Powder Applications: a molecular tool for various biochemical applications Storage: -20 °C Keywords: BSA-PEG2-Xylazine Conjugate, Bovine Serum Albumin-PEG2-Xylazine Conjugate, BSA-Polyethylene Glycol 2-Xylazine…

[chemwhat]

17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecanoic Acid CAS#: 1143516-05-5

IdentificationPhysical DataSpectraRoute of Synthesis (ROS)Safety and HazardsOther Data Identification Product Name17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecanoic AcidIUPAC Name2-acetyl]amino]ethoxy]ethoxy]acetic acid Molecular StructureCAS Registry Number 1143516-05-5MDL NumberMFCD13184942SynonymsAeea-aeea1143516-05-517-amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecan-1-oic acid2-acetyl]amino]ethoxy]ethoxy]acetic acid8-Amino-3,6-dioxaoctanoic acid dimerMFCD1318494217-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecanoic acidH-Adoa-Adoa-OHSCHEMBL1257485AMY3342YQZVQKYXWPIKIX-UHFFFAOYSA-NDTXSID301191445EX-A5417H2N-PEG2-NH-PEG2-CH2COOHZB0899AKOS030213455HY-W125504AC-32527SY251169WS-03066CS-0183820P5002017-amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecan-1-oicacidacetyl- amino}ethoxy)ethoxy]acetic acidacetyl-amino}ethoxy)ethoxy]acetic acidacetylamino}ethoxy)ethoxy]acetic acidacetylamino}ethoxy)ethoxy]acetic acid2-acetamido}ethoxy)ethoxy]acetic acid-acetylamino}-ethoxy)-ethoxy]-acetic acidMolecular FormulaC12H24N2O7Molecular Weight308.33InChIInChI=1S/C12H24N2O7/c13-1-3-18-5-7-20-9-11(15)14-2-4-19-6-8-21-10-12(16)17/h1-10,13H2,(H,14,15)(H,16,17)InChI KeyYQZVQKYXWPIKIX-UHFFFAOYSA-N  Isomeric SMILESC(COCCOCC(=O)NCCOCCOCC(=O)O)N Physical Data AppearancePowder Spectra No data available Route of Synthesis (ROS) Route of Synthesis (ROS) of17-Amino-10-oxo-361215-tetraoxa-9-azaheptadecanoic Acid CAS 1143516-05-5 ConditionsYieldWith N-ethyl-N,N-diisopropylamine In ethanol at 20℃;Experimental ProcedureTo a solution of 2-(1 9-tert-l3utoxycarbonylnonade- canoylamino)pentanedioic acid 1 -tert-butyl ester 5-(2,5-di- oxopyrrolidin-1-yl) ester (2.50 g) and acetylamino}ethoxy)ethoxy]acetic acid (alternative name: H-OEG-OEG-OH)(1 .47 g) in ethanol (40 mE) was added DIPEA (1.26 mE). The mixture was stirred at room temperature overnight and then concentrated in vacuo. To the residue was added aqueous 0.1 N HC1 (150 mE) and ethyl acetate (200 mE). The layers were separated and the aqueous layer was extracted with ethyl acetate (100 mE). The combined organic layers were washed with water and brine, dried (magnesium sulphate) and concentrated in vacuo to give an oil, which crystallised on standing. Yield 96% (3.1 g). ECMS: Theoretical mass: 874.2.Found: 874.49.96%With N-ethyl-N,N-diisopropylamine In ethanol at 20℃;Experimental Procedure16.1 Step 1: 19-{(S)-1-tert-Butoxycarbonyl-3--methoxy}-ethoxy)-ethylcarbamoyl]-propylcarbamoyl}-nonadecanoic acid tert-butyl esterStep 1: 19-{(S)-1-tert-Butoxycarbonyl-3--methoxy}-ethoxy)-ethylcarbamoyl]-propylcarbamoyl}-nonadecanoic acid tert-butyl ester (0556) (0557) To a solution of 2-(19-tert-Butoxycarbonylnonadecanoylamino)pentanedioic acid 1-tert-butyl ester 5-(2,5-dioxopyrrolidin-1-yl) ester (2.50 g, (prepared similarly as described in WO 2005/012347) and acetylamino}ethoxy)ethoxy]acetic acid (1.47 g, alternative name: ∈-amino-3,6-dioxaoctanoic acid dimer, IRIS Biotech GmbH, Cat. No. PEG1221) in ethanol (40 ml) was added DIPEA (1.26 ml). The mixture was stirred at room temperature over night and then concentrated in vacuo. To the residue was added aqueous 0.1 N HCl (150 ml) and ethyl acetate (200 ml). The layers were separated and the aqueous layer was extracted with ethyl acetate (100 ml). The combined organic layers were washed with water and brine, dried (magnesium sulphate) and concentrated in vacuo to give an oil, which crystallized on standing. Yield 96% (3.1 g). LC-MS (electrospray): m/z=874.49.96%With N-ethyl-N,N-diisopropylamine In ethanol at 20℃;96% Safety and Hazards No data available Other Data TransportationStorage at 2~8°, Away from light.StorageStorage at 2~8°, Away from light.Shelf Life1 year DruglikenessLipinski rules componentMolecular Weight308.332logP-2.772HBA9HBD3Matching Lipinski Rules4Veber rules componentPolar Surface Area (PSA)129.34Rotatable Bond (RotB)16Matching Veber Rules1 Use Pattern17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecanoic Acid CAS#: 1143516-05-5 as an intermediate in the synthesis of semaglutide, developing an efficient synthesis route with this intermediate could contribute to the cost-effectiveness of producing semaglutide. Read the full article

[cdbioparticles]

endo-BCN-PEG2-NHS ester

Specifications

Common Use: endo-BCN-PEG2-NHS ester is a PEG derivative containing an NHS ester group and a BCN group. The NHS ester can be used to label the primary amines (-NH0) of proteins, amine-modified oligonucleotides, and other amine-containing molecules. The BCN group can react with azide-tagged biomolecules. The hydrophilic PEG spacer increases solubility in aqueous media.

PEG Molecular Weight: 450.5 g/mol

Functional Group: endo-BCN/NHS ester

[pharmasources]

NH2-PEG2-CH2COOH

Category:Intermediates > Pharmaceutical Intermediates

Product Name:NH2-PEG2-CH2COOH

CAS No.:CAS NO.134978-97-5

Standard:In-house Standards

Price(USD):Negotiable

Company:Hunan HuaTeng Pharmaceutical Co., Ltd.

Basic Info

Grade: pharmaceutical grade

 Factory Location: Changsha, Hunan, China

 Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Asia

 Sample Provided: no

 Payment Terms: L/L

 Huateng Pharma, a professional pharmaceutical intermediate supplier,  provides Semaglutide intermediate 2-(2-(2-Aminoethoxy)ethoxy)acetic acid (CAS No. 134978-97-5) with high quality and purity, which is a medication for the treatment of type 2 diabetes..

https://www.pharmasources.com/products/nh2-peg2-ch2cooh-259141.html

[musicaepica]

Novedad en Spotify: Nuevo álbum de Savfk: Inner Necessity

Míralo aquí: http://epicmusic.family/pEg2

#MúsicaÉpica #EpicMusicFamily #TrailerMusic #CinematicMusic #EpicMusicWorld #Spotify #Music #Album #EpicMusic #MusicaEpica #Novedad #NovedadEnSpotify #Savfk #Spotify

[healthtimetaylor]

Analgesic effect and related amino acids regulation of ginsenoside Rg3 in mouse pain models.

PMID:  Life Sci. 2019 Dec 15 ;239:117083. Epub 2019 Nov 20. PMID: 31759043 Abstract Title:  Analgesic effect and related amino acids regulation of ginsenoside Rg3 in mouse pain models. Abstract:  AIMS: The present study aims to evaluate the analgesic effect of ginsenoside Rg3 in different mouse pain models.MAIN METHODS: Formalin-, carrageenan- and S180 tumor cells induced mouse pain models were built in the study. The licking and biting time and PEG2 contents in the inflammatory sites were measured. The excitatory and inhibitory amino acids in the brains were determined by pre-column derivation FLD-HPLC method.KEY FINDING: We have found that ginsenoside Rg3 treated the pain phases and decreased the PGE2 in formalin and carrageenan induced models, respectively. It significantly increased the contents of EAAs (Asp and Glu) in the brains of S180 tumor inducing pain mice, meanwhile, the IAAs (Gly, Tau and GABA) decreased.SIGNIFICANCE: Our results revealed that ginsenoside Rg3 acted central and peripheral analgesic effect and regulated the inflammatory factors and pain-related amino acids. It could re-balance the abnormal EAAs/IAAs value when the pain occurred. The analgesic mechanism and the clinical application of ginsenoside Rg3 need be evaluated furtherly.

read more

[cancersfakianakis1]

Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus.

Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus.

Cancer Biol Ther. 2017 Apr 10;:0

Authors: Albone EF, Spidel JL, Cheng X, Park YC, Jacob S, Milinichik AZ, Vassen B, Butler J, Kline JB, Grasso L

Abstract The conjugation of toxins, dyes, peptides, or proteins to monoclonal antibodies is often performed via free thiol groups generated by either partial reduction methods or engineering free cysteine residues into the antibody sequence. Antibodies from the rabbit Oryctolagus cuniculus have an additional intrachain disulfide bond, whereby the light chain variable kappa domain is bridged to the constant kappa region between cysteine residues at positions 80 and 171, respectively. Chimerization of rabbit antibodies with human constant domains allows for the generation of a free thiol group at the light chain position 80 (C80) that can be utilized for site-specific conjugation. An efficient process for the purification and simultaneous removal of cysteinylation at the C80 site was developed. The unpaired C80 was shown to be efficiently conjugated using a number of different maleimido-based ligands. REsidue SPEcific Conjugation Technology (RESPECT) antibody-drug conjugates prepared using rabbit-human chimeric anti-human mesothelin rabbit antibodies and maleimido-PEG2-auristatin conjugated to C80 were shown to be highly potent and specific in vitro and effective in vivo in reduction of tumor growth in a highly aggressive mesothelin-expressing xenograft tumor model.

PMID: 28394698 [PubMed - as supplied by publisher]

http://ift.tt/2p0J2G8

[blessedby-puberty]

Peg Leg || Open

Hiccup had secluded himself from the rest of the carnival for the past few weeks. He had been so wrapped up in the new born cubs, he forgot completely about social interaction. But he didn't need that, he didn't need people..So he always reminded himself. 

He sat now in the cage where the cubs were, and smiled to himself. They had opened their eyes by now, and each of them had developed their own personality. The fact that Hiccup could be so close to them, bond with them, blew his mind. He knew that everyone thought he was nuts, he could tell just by the way they watched him with the animals. He didn't know why, but he had always had a special gift with the animals. One that no one else in the entire carnival had.  He never worried about an incident happening, or him getting hurt..Simply because he trusted the animals. All of them. Even his biggest cat, Trixie.

He leaned back, resting on the cage, and watched as the fattest cub wabbled towards him. He let out a chuckle and watched as it started sniffing his leg..Well..The fake one. The chunky cat began to paw at it, and Hiccup knew it wouldn't be good. "Please don't bite that." He mumbled, readjusting himself. He was sure that no one was around, beings he hadn't seen any body in about a week. He pulled his pant leg up, reveling his fake leg,  and slowly removed it. "Not today, bud." He whispered to the cat, setting the leg down beside him.

This was the only time he had taken the leg off outside of his car. Normally he was so self conscious about it, he didn't want anyone to know that it wasn't real. But here with the cubs, that didn't matter. He smiled softly as the chunk laid its head on his stump, closing it's eyes slowly and yawning. He was beginning to think that maybe he could take a nap, as well. That was until he heard rustling behind him. 

"Who's there?!" He called out frantically, torn between waking the cub up to fix his leg, or to let it sleep. Exposing himself. 

[chemwhat]

[2-[2-(Fmoc-amino)ethoxy]ethoxy]acetic acid CAS#: 166108-71-0

IdentificationPhysical DataSpectraRoute of Synthesis (ROS)Safety and HazardsOther Data Identification Product Nameethoxy]acetic acidIUPAC Name2-ethoxy]acetic acidMolecular StructureCAS Registry Number 166108-71-0Synonyms166108-71-0ethoxy]acetic acidFmoc-NH-PEG2-CH2COOH1-(9H-FLUOREN-9-YL)-3-OXO-2,7,10-TRIOXA-4-AZADODECAN-12-OIC ACIDFmoc-8-amino-3,6-dioxaoctanoic acid8-(Fmoc-amino)-3,6-dioxaoctanoic acid{2-ethoxy}acetic acid2-ethoxy]acetic AcidFMOC-AEEAC-OHMFCD01321015FMOC-AMINO-3,6 DIOXAOCTANOIC ACID3,6,11-TRIOXA-9-AZADODECANOIC ACID, 12-(9H-FLUOREN-9-YL)-10-OXO-8-(9-FLUORENYLMETHYLOXYCARBONYL-AMINO)-3,6-DIOXAOCTANOIC ACIDFmoc-Adoa-OH;8-(Fmoc-amino)-3,6-dioxa-octanoic acid;{2--ethoxy}-acetic acid;Fmoc-8-amino-3,6-dioxa-octanoic acidacetic acidFmoc-mini-PEGXQPYRJIMPDBGRW-UHFFFAOYSA-NFmoc-AEEA-OHFMOC-ADOA2,7,10-Trioxa-4-azadodecan-12-oic acid, 1-(9H-fluoren-9-yl)-3-oxo-8--3,6-dioxa-n-octanoic Acidethoxy]acetic AcidFmoc-NH-PEG2-CH2COOH;SCHEMBL259018DTXSID50373231BCP11185TD8147AKOS015840985AB09039CS-W007713HY-W007713AC-26584AM808139AS-17641BP-22044SY0174268-(Fmoc-amino)-3,6-dioxa-n-octanoic AcidF0719FT-06455282-ethoxy]acetic acidEN300-1556421Fmoc-NH-PEG2-CH2COOHFmoc-NH-PEG2-CH2COOHA8106968-(9-Fluorenylmethoxycarbonylamino)-3,6-dioxaoctanoic acid{2-ethoxy}acetic acid, >=95.0% (HPLC)(2-(2-(9H-fluoren-9-ylmethoxycarbonylamino)ethoxy)ethoxy)acetic acidethoxy]ethoxy]acetic Acid2-amino}ethoxy)ethoxy]acetic acid2-{2-CARBONYL}AMINO)ETHOXY]ETHOXY}ACETIC ACID2-ethoxy]acetic acid;1-(9H-Fluoren-9-yl)-3-oxo-2,7,10-trioxa-4-azadodecan-12-oic acidMolecular FormulaC21H23NO6Molecular Weight385.4InChIInChI=1S/C21H23NO6/c23-20(24)14-27-12-11-26-10-9-22-21(25)28-13-19-17-7-3-1-5-15(17)16-6-2-4-8-18(16)19/h1-8,19H,9-14H2,(H,22,25)(H,23,24)InChI KeyXQPYRJIMPDBGRW-UHFFFAOYSA-NIsomeric SMILESC1=CC=C2C(=C1)C(C3=CC=CC=C32)COC(=O)NCCOCCOCC(=O)O Patent InformationPatent IDTitlePublication DateCN114213283Method for preparing ethyoxyl] acetic acid by one-pot method2022 Physical Data AppearanceWhite powder Spectra Description (NMR Spectroscopy)Nucleus (NMR Spectroscopy)Solvents (NMR Spectroscopy)Frequency (NMR Spectroscopy), MHzChemical shifts1Htetradeuteriomethanol3001Htetradeuteriomethanol300Chemical shifts13Ctetradeuteriomethanol Route of Synthesis (ROS) Route of Synthesis (ROS) of ethoxy]acetic acid CAS# 166108-71-0 ConditionsYieldWith anhydrous sodium carbonate In tetrahydrofuran at 15 - 20℃; for 3h;Experimental ProcedureCompound A3 (0.2g, 1.23mmol), 2mL of tetrahydrofuran, 2mL of water and sodium carbonate (0.2g, 1.84mmol) were added to the reaction kettle, the reaction temperature was maintained at 15-20°C, and fluorene methoxycarbonyl succinimide was added. (abbreviated as Fmoc-Osu, 0.4 g, 1.23 mmol) to carry out acylation reaction, after 3 hours of reaction, spot plate to confirm the end point of the reaction, then add ethyl acetate to the reaction solution, adjust pH=2-3 with hydrochloric acid, stand for fractionation The organic phase was washed three times with saturated brine, dried over sodium sulfate, and concentrated to obtain Fmoc-AEEA (0.43 g, yield 91%, purity 99.8%).The purity of Fmoc-AEEA synthesized in this example is 99.8%, and the total yield is 88%×91%×93%×91%=67.78%.91%With Sodium hydrogenocarbonate In ethanol; lithium hydroxide monohydrate for 6h; pH=9;Experimental Procedure Add sodium bicarbonate solid to adjust the product pH of step d to be about 9, then add 140mL of water, 140ml of ethanol, add 42.5g of Fmoc-osu in batches, react 6h after TLC monitoring, after the completion of the reaction; concentrate most of the ethanol under reduced pressure , the pH was adjusted to 2 with hydrochloric acid, crystal seeds were added for crystallization, the solid was precipitated and the crystallization continued for 2 h, filtered and dried to obtain 41.6 g of a white solid, namely ethoxy base]acetic acid.Result detection: the obtained ethoxy]acetic acid has a purity of 99.6% and a yield of 63.2%.63.2%With potassium carbonate In lithium hydroxide monohydrate for 16h; Safety and Hazards Pictogram(s)SignalWarningGHS Hazard StatementsH315 (100%): Causes skin irritation H319 (100%): Causes serious eye irritation H335 (100%): May cause respiratory irritation Precautionary Statement CodesP261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501(The corresponding statement to each P-code can be found at the GHS Classification page.) Other Data TransportationAt room temperature away from lightStorageAt room temperature away from lightShelf Life1 yearMarket Price DruglikenessLipinski rules componentMolecular Weight385.417logP2.159HBA7HBD2Matching Lipinski Rules4Veber rules componentPolar Surface Area (PSA)94.09Rotatable Bond (RotB)12Matching Veber Rules1 Use Patternethoxy]acetic acid CAS#: 166108-71-0 is an intermediate of API Sermaglutide. Read the full article

[pharmasources]

Fmoc-NH-PEG2-CH2COOH

Category:Intermediates > Pharmaceutical Intermediates

Product Name:Fmoc-NH-PEG2-CH2COOH

CAS No.:CAS NO.166108-71-0

Standard:In-house Standards

Price(USD):Negotiable

Company:Hunan HuaTeng Pharmaceutical Co., Ltd.

Basic Info

Grade: pharmaceutical grade

 Factory Location: Changsha, Hunan, China

 Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe

 Sample Provided: no

 Payment Terms: L/L

 Huateng Pharma, a professional pharmaceutical intermediate supplier,  provides Semaglutide intermediate [2-[2-(Fmoc-amino)ethoxy]ethoxy]acetic acid (CAS No. 166108-71-0) with high quality and purity, which is a medication for the treatment of type 2 diabetes.

https://www.pharmasources.com/products/fmoc-nh-peg2-ch2cooh-259142.html

[cancersfakianakis1]

Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus.

Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus.

Cancer Biol Ther. 2017 Apr 10;:0

Authors: Albone EF, Spidel JL, Cheng X, Park YC, Jacob S, Milinichik AZ, Vassen B, Butler J, Kline JB, Grasso L

Abstract The conjugation of toxins, dyes, peptides, or proteins to monoclonal antibodies is often performed via free thiol groups generated by either partial reduction methods or engineering free cysteine residues into the antibody sequence. Antibodies from the rabbit Oryctolagus cuniculus have an additional intrachain disulfide bond, whereby the light chain variable kappa domain is bridged to the constant kappa region between cysteine residues at positions 80 and 171, respectively. Chimerization of rabbit antibodies with human constant domains allows for the generation of a free thiol group at the light chain position 80 (C80) that can be utilized for site-specific conjugation. An efficient process for the purification and simultaneous removal of cysteinylation at the C80 site was developed. The unpaired C80 was shown to be efficiently conjugated using a number of different maleimido-based ligands. REsidue SPEcific Conjugation Technology (RESPECT) antibody-drug conjugates prepared using rabbit-human chimeric anti-human mesothelin rabbit antibodies and maleimido-PEG2-auristatin conjugated to C80 were shown to be highly potent and specific in vitro and effective in vivo in reduction of tumor growth in a highly aggressive mesothelin-expressing xenograft tumor model.

PMID: 28394698 [PubMed - as supplied by publisher]

http://ift.tt/2p0J2G8

[cancersfakianakis1]

Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus.

Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus.

Cancer Biol Ther. 2017 Apr 10;:0

Authors: Albone EF, Spidel JL, Cheng X, Park YC, Jacob S, Milinichik AZ, Vassen B, Butler J, Kline JB, Grasso L

Abstract The conjugation of toxins, dyes, peptides, or proteins to monoclonal antibodies is often performed via free thiol groups generated by either partial reduction methods or engineering free cysteine residues into the antibody sequence. Antibodies from the rabbit Oryctolagus cuniculus have an additional intrachain disulfide bond, whereby the light chain variable kappa domain is bridged to the constant kappa region between cysteine residues at positions 80 and 171, respectively. Chimerization of rabbit antibodies with human constant domains allows for the generation of a free thiol group at the light chain position 80 (C80) that can be utilized for site-specific conjugation. An efficient process for the purification and simultaneous removal of cysteinylation at the C80 site was developed. The unpaired C80 was shown to be efficiently conjugated using a number of different maleimido-based ligands. REsidue SPEcific Conjugation Technology (RESPECT) antibody-drug conjugates prepared using rabbit-human chimeric anti-human mesothelin rabbit antibodies and maleimido-PEG2-auristatin conjugated to C80 were shown to be highly potent and specific in vitro and effective in vivo in reduction of tumor growth in a highly aggressive mesothelin-expressing xenograft tumor model.

PMID: 28394698 [PubMed - as supplied by publisher]

http://ift.tt/2p0J2G8